A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients With Advanced Solid Tumors, With Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients

Trial Profile

A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients With Advanced Solid Tumors, With Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Alpelisib (Primary) ; Everolimus (Primary) ; Exemestane
  • Indications Advanced breast cancer; Neuroendocrine tumours; Pancreatic cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 16 Oct 2016 Planned End Date changed from 1 Apr 2018 to 1 Aug 2017.
    • 16 Oct 2016 Planned primary completion date changed from 1 Apr 2018 to 1 Aug 2017.
    • 16 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top